

Fingolimod (Gilenya, Tascenso ODT)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Fingolimod (Gilenya, Tascenso ODT)	1
Summary	2
Definitions	3
Clinical Indications	4
Medical Necessity Criteria for Clinical Review	4
General Medical Necessity Criteria	4
Medical Necessity Criteria for Initial Clinical Review	5
Initial Indication-Specific Criteria	5
Multiple Sclerosis - Adults	5
Medical Necessity Criteria for Subsequent Clinical Review	6
Subsequent Indication-Specific Criteria	6
Multiple Sclerosis - Adults	6
Experimental or Investigational or Unproven / Not Medically Necessary	7
References	7
Clinical Guideline Revision / History Information	10

Summary

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system. It typically presents in young adults (generally diagnosed before 50 years of age) with symptoms such as vision problems, muscle weakness, numbness, and difficulty with balance and coordination. The most common form is relapsing-remitting MS (occurring in about 85% of patients), characterized by acute attacks followed by periods of remission. Treatment goals include reducing relapses, slowing disability progression, and managing symptoms. Disease-modifying therapies are the primary treatment approach and include injectable medications (e.g., interferons, glatiramer acetate), oral medications (e.g., dimethyl fumarate, fingolimod, teriflunomide, etc.), and infusion therapies (e.g., natalizumab, ocrelizumab).

MS is a progressive disease, meaning that symptoms tend to worsen over time, and it can be classified into several types, including relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS).

Currently, there is no cure for MS, but various treatment options are available to manage symptoms, slow the progression of the disease, and improve quality of life.

- Disease-modifying therapies (DMTs) are a class of medications that target the immune system to reduce inflammation and slow down the progression of the disease. The type of DMT prescribed will depend on the type and severity of MS, as well as the individual's medical history and preferences. Some common DMTs include interferon beta, glatiramer acetate, dimethyl fumarate, and fingolimod.
- High dose corticosteroids, such as high dose intravenous methylprednisolone or oral prednisone can be prescribed to reduce inflammation during acute MS relapses.
- Symptomatic treatments are also available to manage specific symptoms of MS, such as muscle spasms, bladder problems, and depression. Physical therapy, occupational therapy, and speech therapy can help individuals with MS maintain mobility, independence, and communication skills.

Fingolimod, available as Gilenya (capsules) and Tascenso ODT (orally disintegrating tablets), is an FDA-approved sphingosine 1-phosphate (S1P) receptor modulator for treating relapsing forms of multiple sclerosis. It is indicated for patients 10 years and older with clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS). Tascenso ODT has demonstrated bioequivalence to Gilenya capsules in healthy adult subjects.

- It's important to note that fingolimod is not FDA-approved for primary progressive MS (PPMS). While clinical trials in PPMS patients showed that fingolimod had effects on MRI measures of disease activity, it did not significantly impact disability progression. Therefore, its use in PPMS is not supported by current evidence and regulatory approvals.

Definitions

"Clinically isolated syndrome" refers to a first episode of neurologic symptoms lasting at least 24 hours caused by inflammation or demyelination in the central nervous system.

"Compendia" are summaries of drug information and medical evidence to support decision-making about the appropriate use of drugs and medical procedures. Examples include, but are not limited to:

1. American Hospital Formulary Service Drug Information
2. Clinical pharmacology
3. National Comprehensive Cancer Network Drugs and Biologics Compendium
4. Thomson Micromedex DrugDex
5. United States Pharmacopeia-National Formulary (USP-NF)

"Disease-modifying therapy" is a medication that modifies the course of MS by reducing relapses and slowing disability progression.

"Documentation" refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or
- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

"MRI" or "Magnetic Resonance Imaging" refers to a medical imaging technique that creates detailed three-dimensional (3D) images of the organs and tissues in your body. A brain MRI can reveal areas of active MS disease called lesions within the central nervous system.

"Multiple sclerosis" is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and neurodegeneration.

"No evidence of" indicates that the reviewer has not identified any records of the specified item or condition within the submitted materials or claims history. In the absence of such evidence, the member is considered eligible. If any evidence of the item or condition is present upon review of the request, the member does not qualify.

"Primary progressive MS" refers to worsening neurologic function from the onset of symptoms, without early relapses or remissions.

"Relapse" is defined as the appearance of new symptoms or the worsening of existing symptoms lasting at least 24 hours in the absence of fever or infection.

"Relapsing-remitting MS" refers to a disease course characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery.

"Secondary progressive MS" is a disease course following relapsing-remitting MS that is characterized by a progressive worsening of neurologic function over time with or without relapses.

"[s]" indicates state mandates may apply.

Clinical Indications

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

The Plan considers fingolimod (Gilenya, Tascenso ODT) medically necessary when ONE of the following criteria are met:

1. The member meets ALL of the following:
 - a. Authorization may be granted for pediatric members less than 18 years of age with multiple sclerosis when there is documentation that the benefits outweigh the risks; *and Note: If approved, the requested product will be authorized for up until the member reaches 18 years of age.*
 - b. The member meets ONE of the following:
 - i. IF the request is for brand Gilenya 0.25 mg, the member weighs less than or equal to (\leq) 40 kg; *or*
 - ii. IF the request is for brand Gilenya 0.5 mg, the member is unable to use, or has tried and failed generic fingolimod 0.5 mg capsules from TWO (2) different manufacturers^[s]; *or*
 - iii. IF the request is for Tascenso 0.25 mg, the member meets ALL of the following:
 1. The member is unable to swallow fingolimod capsules^[s]; *and*
 2. The member weighs less than or equal to (\leq) 40 kg; *or*
 - iv. IF the request is for Tascenso 0.5 mg ODT, the member meets ONE of the following:
 1. The member is unable to swallow fingolimod capsules^[s]; *or*
 2. The member is unable to use, or has tried and failed generic fingolimod 0.5 mg capsules from TWO (2) different manufacturers^[s]; *OR*
2. The member meets the applicable [Medical Necessity Criteria for Initial Clinical Review](#) or [Subsequent Clinical Review](#) listed below.

Medical Necessity Criteria for Initial Clinical Review

Initial Indication-Specific Criteria

Multiple Sclerosis - Adults

The Plan considers fingolimod (Gilenya, Tascenso ODT) medically necessary when recent (within the last 3 months) clinical chart documentation provided indicates the member meets ALL of the following:

1. Prescribed by or in consultation with a neurologist or physician who specializes in the treatment of multiple sclerosis; *AND*
2. The member has ONE (1) of the following forms of multiple sclerosis:
 - a. Relapsing-remitting (RRMS); *or*
 - b. Active secondary progressive disease (SPMS); *or*
 - c. Clinically isolated syndrome (CIS); *AND*
3. IF the request is for Gilenya, the member meets ONE (1) of the following:
 - a. For Brand Gilenya 0.5 mg, the member is unable to use, or has tried and failed BOTH of the following^[s]:
 - i. Generic fingolimod 0.5 mg capsules from TWO (2) different manufacturers; *and*
 - ii. TWO (2) of the following:
 1. An interferon beta product (e.g., Avonex, Betaseron, Plegridy, or Rebif); *and/or*
 2. Dimethyl Fumarate (generic Tecfidera); *and/or*
 3. Glatiramer acetate (Copaxone); *and/or*
 4. Teriflunomide (generic Aubagio); *OR*
4. IF the request is for Tascenso 0.5 mg ODT, the member meets ONE (1) of the following:
 - a. The member is unable to use, or has tried and failed BOTH of the following^[s]:
 - i. Generic fingolimod 0.5 mg capsules from TWO (2) different manufacturers; *and*
 - ii. TWO (2) of the following:
 1. An interferon beta product (Avonex, Betaseron, Plegridy, or Rebif); *and/or*
 2. Dimethyl Fumarate (generic Tecfidera); *and/or*
 3. Glatiramer acetate (Copaxone); *and/or*
 4. Teriflunomide (generic Aubagio); *OR*
 - b. The member meets BOTH of the following:
 - i. The member is unable to swallow fingolimod capsules^[s]; *and*
 - ii. The member weighs greater than (>) 40 kg; *AND*
5. The member meets ALL of the following:
 - a. No evidence of recent (within last 6 months) myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or decompensated heart failure requiring hospitalization; *and/or*
 - b. No evidence of Class III or IV heart failure; *and/or*

- c. No evidence of Mobitz type II second-degree or third-degree AV block or sick sinus syndrome, unless member has a functioning pacemaker; *and/or*
 - d. No evidence of baseline QTc interval \geq 500 msec; *and/or*
 - e. No evidence of cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs; *AND*
6. Fingolimod (Gilenya, Tascenso ODT) will be used as monotherapy for multiple sclerosis (i.e., member is not using and will not use other disease-modifying MS therapies while on fingolimod); *AND*
 7. Fingolimod (Gilenya, Tascenso ODT) is being prescribed at a dose and frequency that is within FDA approved labeling OR is supported by compendia or evidence-based published dosing guidelines for the requested indication.

The requested medication is being used within the Plan's Quantity Limit of:

 - o *For adults (18 years and older): 0.5 mg orally once daily.*

If the above prior authorization criteria are met, the requested medication will be authorized for up to 12-months.^[s]

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Subsequent Indication-Specific Criteria

Multiple Sclerosis - Adults

The Plan considers fingolimod (Gilenya, Tascenso ODT) medically necessary when recent (within the last 6 months) clinical chart documentation provided indicates the member meets BOTH of the following:

1. The requested medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis; *AND*
2. The member has experienced at least ONE (1) of the following:
 - a. Improvement in at least ONE (1) objective measure, such as:
 - i. Reduced disease activity on MRI; *and/or*
 - ii. Improved or stable disability scores; *and/or*
 - iii. Reduced relapse rate; *and/or*
 - iv. Improved fatigue or walking assessments; *AND/OR*
 - b. The member has shown stabilization or improvement in at least ONE (1) MS symptom, such as:
 - i. Motor function; *and/or*
 - ii. Fatigue; *and/or*
 - iii. Vision; *and/or*
 - iv. Bowel/bladder function; *and/or*
 - v. Spasticity; *and/or*

- vi. Walking/gait; *and/or*
- vii. Pain/numbness/tingling.

If the above reauthorization criteria are met, the requested medication will be authorized for up to 12-months.^[s]

Experimental or Investigational or Unproven / Not Medically Necessary^[s]

Fingolimod (Gilenya, Tascenso ODT) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- Treatment of other neurological conditions not related to multiple sclerosis. While fingolimod has been studied in some other neurological conditions (e.g., chronic inflammatory demyelinating polyneuropathy), current evidence does not support its use outside of relapsing forms of MS.
- Use for the treatment of non-relapsing forms of multiple sclerosis. Current evidence does not support the efficacy of fingolimod (Gilenya, Tascenso ODT) in PPMS. The INFORMS trial showed that fingolimod did not slow disease progression in PPMS patients.
- Use in combination with other disease-modifying therapies for multiple sclerosis. There is insufficient evidence to support the safety and efficacy of combining fingolimod with other DMTs.

References

1. Bainbridge JL, Miravalle A, Wong PS. Multiple Sclerosis. In DiPiro JT, Yee GC, Posey LM, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 11th ed. New York, NY: McGraw-Hill; 2019.
2. Benallegue N, Rollot F, Wiertelwski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA; OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2024 Mar 1;81(3):273-282.
3. Calabresi PA, Radue EW, Goodin D, et al,. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.
4. Chitnis T, Tenenbaum S, Banwell B, Krupp L, Pohl D, Rostasy K, Yeh EA, Bykova O, Wassmer E, Tardieu M, Kornberg A, Ghezzi A; International Pediatric Multiple Sclerosis Study Group. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012 Jan;18(1):116-27.
5. Cohen JA, Barkhof F, Comi G, et al,. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
6. Cohen JA, Khatri B, Barkhof F, et al,. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neuro

- Neurosurg Psychiatry. 2016 May;87(5):468-75. doi: 10.1136/jnnp-2015-310597. Epub 2015 Jun 25.
7. Derfuss T, Bergvall NK, Sfikas N, Tomic DL. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. *Curr Med Res Opin.* 2015;31(9):1687-91. doi: 10.1185/03007995.2015.1067191. Epub 2015 Aug 20. .
 8. de Souza Wagner PH, de Paiva FA, Mello JS, et al. Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis. *J Neurol.* 2025 Jul 30;272(8):546. doi: 10.1007/s00415-025-13283-x.
 9. Diouf I, Malpas CB, Sharmin S, et al,. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. *J Neurol Neurosurg Psychiatry.* 2023 Dec;94(12):1004-1011. doi: 10.1136/jnnp-2023-331499. Epub 2023 Jul 6.
 10. Gilenya (fingolimod) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2025.
 11. Hauser, S., & Cree, B. (2020). Treatment of Multiple Sclerosis: A Review.. *The American journal of medicine.* <https://doi.org/10.1016/j.amjmed.2020.05.049>.
 12. He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurol.* 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18.
 13. Hughes R, Dalakas MC, Merkies I et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. *Lancet Neurol.* 2018; 17:689-698.
 14. Irmak Ön B, Havla J, Mansmann U. Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosis. *Mult Scler Relat Disord.* 2025 Jan;93:106247. doi: 10.1016/j.msard.2024.106247. Epub 2024 Dec 21.
 15. Kappos L, Antel J, Comi G, et al,. Oral fingolimod (FTY720) for relapsing multiple sclerosis. *N Engl J Med.* 2006 Sep 14;355(11):1124-40. doi: 10.1056/NEJMoa052643. P
 16. Kappos L, O'Connor P, Radue EW, et al,. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. *Neurology.* 2015 Apr 14;84(15):1582-91. doi: 10.1212/WNL.0000000000001462. Epub 2015 Mar 20.
 17. Kappos L, Radue EW, O'Connor P, et al,. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
 18. Köhler M, Paul F, Janke K, et al. Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment - a systematic review and network meta-analysis. *BMC Neurol.* 2025 Aug 9;25(1):328. doi: 10.1186/s12883-025-04338-7.
 19. Krysko KM, Graves JS, Rensel M, et al; US Network of Pediatric MS Centers. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. *Ann Neurol.* 2020 Jul;88(1):42-55.
 20. Krysko KM, Graves J, Rensel M, et al; US Network of Pediatric MS Centers. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. *Neurology.* 2018 Nov 6;91(19):e1778-e1787.
 21. Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. *J Neurol.* 2020 Dec;267(12):3489-3498. doi: 10.1007/s00415-019-09395-w. Epub 2019 May 25.
 22. Longbrake EE, Kantor D, Pawate S, et al. Effectiveness of alternative dose fingolimod for multiple sclerosis. *Neurol Clin Pract.* 2018;8(2):102-107. doi: 10.1212/CPJ.0000000000000434.
 23. Lublin F, Miller DH, Freedman MS et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet.* 2016; 387:1075-1084.
 24. Lublin F, Miller DH, Freedman MS, et al,. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet.*

- 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Erratum in: *Lancet*. 2017 Jan 21;389(10066):254. doi: 10.1016/S0140-6736(17)30042-9.
25. Luzzio C, Dangond F. Multiple Sclerosis Guidelines. MedScape. 12 March 2024. Available at: <https://emedicine.medscape.com/article/1146199-guidelines#g1>. Accessed 20 January 2026.
 26. Mahdi-Rogers M, Brassington R, Gunn AA et al. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. *Cochrane Database Syst Rev*. 2017; 5:CD003280.
 27. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. *JAMA*. 2021;325(8):765–779. doi:10.1001/jama.2020.26858
 28. Montalban X et al:ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. *Eur J Neurol*. 25(2):215-37, 2018
 29. Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. *Lancet Neurol*. 2025 Oct;24(10):850-865. doi: 10.1016/S1474-4422(25)00270-4. Erratum in: *Lancet Neurol*. 2025 Nov;24(11):e13. doi: 10.1016/S1474-4422(25)00355-2.
 30. Multiple Sclerosis Society of Canada. Disease-modifying therapies. <https://mssociety.ca/managing-ms/treatments/medications/disease-modifying-therapies-dmts>.
 31. National Institute for Health and Care Excellence [NICE]. Multiple sclerosis in adults: management. NICE Guidelines [NG220]. 22 June 2022. Available at: <https://www.nice.org.uk/guidance/ng220/chapter/Recommendations#ms-symptom-management-and-rehabilitation>. Accessed 20 January 2026.
 32. National MS Society. Disease-modifying therapies for MS (updated March 2022). Available from National MS Society website: <https://nms2cdn.azureedge.net/cmssite/nationalmssociety/media/msnationalfiles/brochures/brochure-the-ms-disease-modifying-medications.pdf>.
 33. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018;90(17):777-788.
 34. Rashid W, Ciccarelli O, Leary SM, et al. Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. *Pract Neurol*. 2025 Jan 16;25(1):18-24. doi: 10.1136/pn-2024-004228.
 35. Reich DS, Lucchinetti CF, Calabresi PA. 2018. Multiple sclerosis. *New England Journal of Medicine* 378(2):169-180
 36. Sladowska K, Mocko P, Brzostek T, et al. Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies. *Mult Scler Relat Disord*. 2025. doi: 10.1016/j.msard.2025.106263
 37. Tascenzo ODT (fingolimod) [prescribing information]. Cambridge, United Kingdom: Cycle Pharmaceuticals Ltd; January 2025.
 38. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence summary. Multiple Sclerosis Coalition. Available from the National MS Society Website: <https://www.nationalmssociety.org/>.
 39. Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. *Cochrane Database Syst Rev* 2015;9:CD011381.
 40. Walsh R, Chitnis T. Therapeutic Advances in Pediatric Multiple Sclerosis. *Children*. 2025;12(3):259.
 41. Yang, J., Rempe, T., Whitmire, N., Dunn-Pirio, A., & Graves, J. (2022). Therapeutic Advances in Multiple Sclerosis. *Frontiers in Neurology*, 13. <https://doi.org/10.3389/fneur.2022.824926>.

Clinical Guideline Revision / History Information

Original Date: 06/27/2024

Reviewed/Revised: 10/01/2025, 05/01/2026